A 2025 argument about Medicaid coverage put GLP-1 medicines at the center of a state-budget question: whether to ab

A 2025 argument about Medicaid coverage put GLP-1 medicines at the center of a state-budget question: whether to absorb high near-term drug costs in pursuit of possible longer-term health gains. The relevant public action would be made state by state, not by a single national rule.

For people enrolled in Medicaid, the consequence is that access can depend on a state benefit design rather than on the existence of a prescription. States face the same basic tension between immediate spending, uncertain savings, and a large potentially eligible population.

This was a policy argument, not a final expansion or a universal budget result. State rules, prices, and evidence assessments vary, so the record does not establish coverage for any individual.

Read the full story at The Atlantic ↗